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Objective: To identify conditions associated with severe carbon monoxide transfer coefficient
reduction (Kco < 40% of predicted values).
Patients and methods: We retrospectively reviewed pulmonary function tests, such as Kco
measurement, in consecutive patients evaluated in the physiology unit of a University hospital
over a 6-year period. Patients were included if they had at least 1 measure of severe Kco
reduction, with further detailed pulmonary function tests, clinical data, and diagnostic proce-
dures conducted within 6 months.
Results: 5576 patients underwent 9061 Kco measurements. 195 patients (3.5%) with Kco < 40%
were investigated (156 males; mean age 62  12 years). Mean Kco was 29  9% of predicted
values. The main conditions associated with severe Kco reduction were: emphysema (46%);
interstitial lung disease (28%); combined pulmonary fibrosis and emphysema (16%); and pre-
capillary pulmonary hypertension (8%). Systolic pulmonary artery pressure was 35 mmHg at
echocardiography in 88% of patients. Right heart catheterization performed in 97 patients
showed pre-capillary pulmonary hypertension in 86 of 195 patients (44%). Pulmonary hyperten-
sion was the most frequent condition associated with Kco severe reduction. Pulmonarytive pulmonary disease; CPFE, combined pulmonary fibrosis and emphysema; FEV1, forced expiratory
acity; HRCT, high-resolution computed tomography; ILD, interstitial lung disease; IPF, idiopathic
oxide diffusion coefficient; mPAP, mean pulmonary arterial pressure; NSIP, non-specific interstitial
ssociation; PaO2, partial pressure of oxygen in arterial blood; PCWP, pulmonary capillary wedge
; PFTs, pulmonary function tests; SpO2, peripheral oxygen saturation; TLco, carbon monoxide transfer
ia.
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Etiologies of very low Kco 1249hypertension was present in 29%, 53%, and 48% of patients with chronic obstructive pulmonary
disease, interstitial lung disease, and combined pulmonary fibrosis and emphysema, respec-
tively, and was disproportionate to the parenchymal lung disease (mean pulmonary artery
pressure > 35 mmHg) in 63% of cases.
Conclusion: Severe Kco reduction is frequently related to pulmonary hypertension, especially
when associated with emphysema and/or interstitial lung disease. Systematic echocardiog-
raphy is thus warranted in any patient with severe Kco diminution.
ª 2011 Elsevier Ltd. All rights reserved.Pulmonary gas exchange across the alveolar-capillary
membrane1 is assessed by carbon monoxide transfer factor
(TLco) (or diffusion factor DLco) and the diffusion coeffi-
cient (Kco) as they respectively provide quantitative and
qualitative measures of gas transfer in the lungs.2,3 Diffusing
capacity is interpreted in conjunction with spirometry and
lung volumes; TLco can be construed in terms of its
components, namely Kco and alveolar volume2; hence, the
relevance of adjusting TLco to alveolar volume with Kco
(also called DLco/VA).3 Decreased Kco, considered to
reflect qualitative impairment of the alveolar-capillary
membrane, is associated with conditions of diffuse alveolar-
capillary disease (e.g. idiopathic pulmonary fibrosis, IPF),
reduced alveolar surface or capillary density (e.g. emphy-
sema, pulmonary hypertension, PH), or diminished hemo-
globin level.3 TLco impairment has been reported to be
a predictor of mortality in various conditions with distinct
pathophysiologies, such as chronic obstructive pulmonary
disease (COPD),4 IPF,5 systemic sclerosis-associated
interstitial lung disease (ILD)6 and pulmonary arterial
hypertension.7
To better reflect disease severity in conditions associated
with TLco and/or Kco reduction (e.g. <80% of predicted
values), 3 grades of gravity have been arbitrarily established
by the American Thoracic Society and the European Respi-
ratory Society.8 A decline of TLco or Kco is considered to be
mild when it ranges from >60% of predicted values to the
lower limit of normal;moderate, when it comprises between
40% and 60% of predicted values; and severe, when it is<40%
of predicted values.
Although the possible causes of decreased Kco have
been well identified,2 and despite the large population of
patients affected by pulmonary diseases that may affect
Kco, the relative distribution of conditions associated with
severe Kco reduction has not been reported. The aim of the
present study was to identify the conditions associated to
severe Kco impairment in consecutive patients evaluated
for pulmonary function.Patients and methodsCase selection
We retrospectively reviewed the electronic database of the
Lung Physiology Unit of our university hospital, comprising
all consecutive pulmonary function tests (PFTs) between
January 1, 2003 and December 31, 2008. Tests were con-
ducted in both out-patients and hospitalized-patients,
mostly from the Department of Respiratory Medicine of thesame hospital, which serves as the national reference
centre for rare pulmonary diseases, a regional referral
centre for PH and lung transplantation, and a local referral
centre in general pulmonary medicine.
The following criteria had to be met for inclusion: 1. At
least 1 Kco measurement <40% of predicted values; 2.
Clinical data and diagnostic investigations (high-resolution
computed tomography (HRCT) scan of the chest and/or
echocardiography and/or other assessments as needed)
obtainedwithin 6months of PFTs and available for review; 3.
Complete PFTs performed at the time of Kco measurement,
as indicated below. The clinical data on cases meeting the
inclusion criteria were collected retrospectively.
Investigations were undertaken as part of routine eval-
uations during the clinical care of patients. The database
was anonymous. According to French legislation, written
informed consent is not required for retrospective collec-
tion of data corresponding to current practice.
Clinical analysis
Medical records were reviewed with a standardized form for
the following data that were systematically present in them,
allowing an exhaustive review of age, gender, smoking
history, New York Heart Association (NYHA) functional class
of dyspnea, pulmonary auscultation, and finger clubbing.
Smoking status was classified as: “never-smokers”, “ex-
smokers” for patients who stopped smoking at least 6months
before the Kco recording, or “current-smokers”.
Pulmonary function tests
PFTs were performed according to standard procedures and
following international guidelines, i.e. recommendations of
the European Respiratory Society until 2005,1,9 then joint
guidelines of the American Thoracic Society and the Euro-
pean Respiratory Society.1,10,11 Lung volume was measured
bywhole-body plethysmograph (JaegerMasterscreen Body,
Sebbac, Wuerzburg, Germany), and data were expressed as
percentages of published predicted values.9 PFT accuracy
was verified by daily calibration of plethysmograph. Cali-
bration was obtained in healthy subjects for the assessment
of static and dynamic lung volumes as per international
guidelines.10,11
Diffusion capacity was quantified by the single-breath
method, using the Morgan Benchmark transfer test, which
is a single-sample gas analyzer system displaying only
volume over time. The discarded volume of dead space and
the sample gas volume were 500 ml and 900 ml, respec-
tively, according to vital capacity. Vital capacity was higher
1250 L. Kiakouama et al.than 1300 ml in all patients, ensuring a minimal washout
volume of 500 ml and a minimal sample gas volume of
800 ml in all patients. Tests were considered as acceptable
when they corresponded to published guidelines of the
American Thoracic Society and the European Respiratory
Society.1 All patients had at least two acceptable tests that
met the repeatability requirement of being within 10% of
the highest value. The data were corrected for hemoglobin
following guidelines, and expressed as percentages of
published predicted values,9 and divided by alveolar
volume.1 The zeroing procedure of gas analyzers was
checked prior to each test for quality assurance. Discrep-
ancies between inspired volume and volume capacity but
also alveolar volume and total lung capacity were carefully
noted and corrected. In case of suspected problems, tests
were performed for leakage. Moreover, DLco measure-
ments were performed in a healthy subject to ensure
variability of less than 10% in DLco and Kco. Linearity or the
gas analyzer was verified every 3 months.
Lung volumes were considered normal when they
comprised between 80% and 120% of predicted values.
Airflow obstruction was defined by forced expiratory volume
in 1 s (FEV1)/forced vital capacity (FVC) < 70%. Severe Kco
reduction was defined as being <40% of predicted value.8
The 6-minwalk test was performed tomeasure functional
exercise capacity, according to international guidelines,12
with oxygen saturation measured by pulse oximetry using
a finger probe at rest and just before the end of the exercise.
High-resolution computed tomography
Chest HRCTwas undertakenwith a spiral Philips scanner, and
the images were reviewed by an experienced radiologist and
a pneumologist unaware of the results of Kco measurement,
with consensus evaluation in case of discrepancy.
HRCT findings were appraised according to Fleischner
nomenclature.13 Emphysema was defined by areas of lung
parenchyma with abnormally low attenuation or bullae (air
spaces > 1 cm in diameter delimited by a very thin wall
(<1 mm) or no wall), and classified as centrilobular, pan-
lobular or paraseptal emphysema.13
HRCT patterns of ILD were classified as being consistent
with usual interstitial pneumonia (UIP), non-specific inter-
stitial pneumonia (NSIP), or other. They were considered as
consistent for UIP according to the following criteria: retic-
ulation in all lobes with basal and peripheral predominance,
traction bronchiectasis, honeycombing with minimal or no
ground glass opacity. The HRCT patterns of NSIP featured
reticulation, ground glass opacity, and basal predominance,
without honeycombing.14
Cardiac and hemodynamic assessment
Echocardiography was performed by experienced cardiolo-
gists with expertise in PH. Left ventricular ejection fraction,
right ventricular dimensions and function were recorded.
Systolic pulmonary arterial pressure was estimated by
quantifying the maximal velocity of tricuspid regurgitation
and adding a 2-dimensional estimate of right atrial pressure.
Right cardiac catheterization was performed in patients
with Doppler echocardiography of peak tricuspidregurgitation velocity > 3.0 m/s (or transtricuspid
gradient > 36 mmHg), a history of right heart failure and/or
dilated right heart cavities with unexplained dyspnea. Right
heart catheterization was achieved as described else-
where.15 Pre-capillary PH was defined as resting mean
pulmonary arterial pressure (mPAP) 25 mmHg, with
pulmonary capillary wedge pressure (PCWP)  15 mmHg
and normal or reduced cardiac output.16
Diagnostic standards
The whole medical chart was reviewed to agree on a final
clinical diagnosis (by LK, VC, JFC). The diagnosis of COPD
followed international standards.17 The diagnosis of IPF and
other idiopathic interstitial pneumonias followed interna-
tional guidelines.18 The syndrome of combined pulmonary
fibrosis and emphysema (CPFE) was defined.19 Sarcoidosis
was diagnosed as described.20 Lymphangioleiomyomatosis
was diagnosed according to criteria proposed by a European
Respiratory Society Taskforce.21 Hypersensitivity pneumo-
nitis was diagnosed with a published diagnostic protocol.22
Pulmonary Langerhans cell histiocytosis was diagnosed as
per the algorithm proposed by Vassallo et al.23 The criteria
for the diagnosis of systemic lupus erythematosus and
systemic sclerosis were those of the American College of
Rheumatology.24,25 The etiologic classification of PH fol-
lowed recent guidelines.16 PH was considered dispropor-
tionate in patients with parenchymal disease when mean
pulmonary artery pressure was >35 mmHg.26
Data analysis
Statistical analysis of dichotomous variables was performed
using 2-sided Fisher’s exact test. Kruskal Wallis test was used
for the comparison of continuous variables. Pearson’s
method was used for correlations. Analyses were performed
with SPSS 17.0 for Windows with significance established
at p < 0.05.
Results
Patients
During the study period, 9061 PFTs, including Kco measure-
ments, were performed in 5576 successive patients. Of
these, 201 patients (3.6%) had Kco< 40% of predicted values.
Six patients were excluded because of data missing in
their medical charts, and thus 195 patients (3.5%) were
investigated.
Clinical characteristics
The demographic data on these 195 patients are reported in
Table 1. There were 156 males (80%) and 39 females, with
a mean  standard deviation (SD) age of 62  12 years
(range, 27e85). Sixty-five (33%) were current smokers, 95
(49%) were ex-smokers, and 35 (18%) were non-smokers.
Dyspnea was present in all patients, with 63% of patients in
NYHA functional class III or IV.
Table 1 Clinical characteristics of patients with severe
carbon monoxide diffusion coefficient reduction.
Sex, males:females 156:39
Mean age  SD
(range), years
62  12 (27e85)
Mean BMI  SD
(range), kg/m2
24  4 (10e41)
Current smokers 33%
Ex-smokers 49%
Non-smokers 18%
Mean pack-years  SD
(range)
32  27 (0e125)
NYHA class I 5%
NYHA class II 32%
NYHA class III 53%
NYHA class IV 10%
FVC, % predicted 89  22 (42e139)
FEV1, % predicted 61  25 (15e114)
FEV1/FVC, % 52  20 (16e98)
TLC, % predicted 97  26 (36e161)
DLco, % predicted 29  9% (2e39.9)
Kco, % predicted 28%  12% (2e58)
PaO2 at rest, kPa 8  2 kPa (4e14)
6-min walk distance, m 320  139 m (20e640)
SpO2 following 6-min
walk test, %
82  8 m (52e98)
Decrease in SpO2
during 6-min walk test, %
10  7% (2; 28)
BMI, body mass index; DLco, single-breath diffusing capacity of
the lung for carbon monoxide; FEV1, forced expiratory volume
in 1 s; FVC, forced vital capacity; Kco, single-breath transfer
factor of the lungs for carbon monoxide; NYHA, New York Heart
Association; PaO2, partial pressure of oxygen in arterial blood;
SpO2, peripheral oxygen saturation; TLC, total lung capacity.
Data are mean  standard deviation (range).
Etiologies of very low Kco 1251Pulmonary function tests
Mean SDKco in 195patientswas 29 9%of predicted values
(Table 1). Only 28 patients (14%) had TLco> 40% of predicted
values. An obstructive ventilatory defect, as shown by FEV1/
FVC < 70%, was found in 148 patients (76%), including 123
(63%) with FEV1 < 80% of predicted values. A restrictive
pattern, defined as total lung capacity <80% of predicted
values, was observed in 46 patients (24%). Sixteen patients
(8%) had a mixed ventilatory defect. Peripheral oxygen
saturation (SpO2) measured by pulse oximetry during 6-min
walking test decreased by 4% in 85% of patients.
Values of Kco were lower in patients with higher func-
tional classes (p Z 0.0003) (Fig. 1). Kco significantly corre-
latedwith 6-minwalking distance (rZ 0.304,p< 0.0001) and
inversely correlated with percent decrease in SpO2 during
the 6-min walking test (rZ 0.384, p < 0.0001).
High-resolution computed tomography of the chest
HRCT scan of the chest showed emphysema in 121 (62%) of
187 patients, further categorized into centrilobular (36%),
paraseptal (20%), and panlobular (6%) emphysema. All
patients with COPD had emphysema at HRCT.Features of ILD were apparent in 86 patients (44%),
including 31 with CPFE; 10 patients with a pattern of UIP/
IPF; 15 patients with pulmonary cysts associated with
lymphangioleiomyomatosis (9 patients) or pulmonary
Langerhans cell histiocytosis (6 patients); 7 patients with
hypersensitivity pneumonitis and typical HRCT pattern; 1
patient with a pattern suggestive of non-specific interstitial
pneumonia; 2 patients with a prominent crazy-paving
pattern related to alveolar proteinosis; 3 patients with
sarcoidosis and typical pattern; and 17 with other or
unclassifiable HRCT patterns.
In 31 patients (16%), emphysema was associated with
ILD, with bibasilar reticular abnormalities, traction bron-
chiectasis and/or honeycombing on HRCT, fulfilling criteria
for the diagnosis of CPFE.
Pulmonary hypertension
One hundred and sixty-nine patients (87%) underwent
echocardiography, including 4 with inconclusive results due
to low quality signals, 19 with normal results without esti-
mation of pulmonary pressures, and 8 with indirect evidence
of PH but without possible pulmonary pressure estimation.
Systolic pulmonary artery pressure was estimated to be
60  23 mmHg (range, 20e122) in the remaining 138
patients, 35 mmHg in 121 patients (representing 88% of
tested patients), and 45 mmHg in 99 patients (72%).
Right-sided heart catheterization in 97 patients showed
pre-capillary PH in 86 cases (44%), including 12 patients
(6%) with pulmonary arterial hypertension, 3 patients (2%)
with chronic thromboembolic pulmonary disease, and 70
patients (36%) with chronic respiratory disease-associated
PH. mPAP in PH patients was 43  12 mmHg (range, 25e85),
mean cardiac index was 2.3  0.5 L m2 (range, 1.8e3.3),
mean PCWP was 10  3 mmHg (range, 3e14), and mean
pulmonary vascular resistance was 725  388 dyn s cm5
(range, 232e2071). The median 6-min walking distance in
patients with PH was 269 m (range, 40e546). No correlation
was found between Kco expressed as percent of predicted
values and mean PAP (r Z 0.061, p Z 0.554) (Fig. 1).
Final diagnosis
The distribution of final diagnosis in patients with severe
Kco reduction is reported in Table 2. The main causes were
COPD with emphysema (46%), ILD (28%), CPFE (16%), and
pre-capillary PH (8%). In most patients, the severity of
disease and/or PH did not allow surgical biopsy. However,
histopathological examination of video-assisted lung biopsy
and/or of an explanted lung was available in 26 patients
(12%), including 6 with a diagnosis of IPF, 4 with pulmonary
Langerhans cell histiocytosis, 7 with lymphangioleiomyo-
matosis, 5 with emphysema, 2 with unclassifiable ILD, 1
with NSIP, and 1 with hypersensitivity pneumonitis.
Thirty-one patients (16%) had both emphysema and
features of pulmonary fibrosis at imaging, meeting the
characteristics of CPFE syndrome, including 14 patients
(7%) with pre-capillary PH confirmed at right-sided heart
catheterization. Further evaluation of patients with CPFE
and severe Kco alteration is reported in Table 3. Nine
patients were included in previous studies.19,27
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Figure 1 Correlation between carbon monoxide transfer coefficient (Kco) expressed as percent of predicted values and 6-min
walking distance (A), percent decrease in peripheral oxygen saturation (SpO2) during the 6-min walking test (B), and mean
pulmonary arterial pressure (mean PAP) (C). D, relationships between New York Heart Association functional class and Kco. Group
1, chronic obstructive pulmonary disease with emphysema; group 2, interstitial lung disease; group 3, combined pulmonary fibrosis
and emphysema; group 4, pre-capillary pulmonary hypertension; group 5, other.
1252 L. Kiakouama et al.The mean value of Kco did not significantly differ
between patients with COPD, ILD, pre-capillary PH, or CPFE
(data not shown). The functional class did not significantly
differ according to etiological groups.
Pre-capillary PH (pulmonary arterial hypertension or
chronic thromboembolic pulmonary disease), present in 86
patients (44%),was thefinal solitarydiagnosis in8%ofthestudy
population, representing 17%of thepatientswithpre-capillary
PH. Pre-capillary PHwas associated with chronic parenchymal
respiratory disease in 70 patients (36% of the study pop-
ulation), representing 82% of patients with pre-capillary PH.
PHwas present in 29% of the 90 patients with COPD, 53% of the
55 patients with ILD, and 48% of the 31 patients with CPFE. In
addition, PH was disproportionate (mPAP> 35 mmHg) in 69%,
55%, and 67% of patientswith PHassociatedwith COPD, ILD, or
CPFE, respectively, overall corresponding to 63% of PH asso-
ciated with parenchymal lung disease.Discussion
To our knowledge, this is the first study to address the
variety of conditions associated with a severe CO diffusioncoefficient reduction (Kco < 40%). In the setting of
a University hospital serving as a referral center for rare
pulmonary diseases, PH, lung transplantation, and general
pulmonology, 3.6% of consecutive patients who were eval-
uated for PFTs, including TLco measurement, had Kco< 40%
of predicted values. PH associated with emphysema and/or
ILD, or alone, accounted for 44% of patients and was the
most frequent condition associated with Kco reduction. Of
note, 82% of patients were smokers. Exercise capacity was
severely impaired, with 63% in dyspnea functional class III or
IV, a mean 6-min walk distance of only 296 m, and mean
desaturation of 13%.
Given its prevalence, it is not surprising that COPD and
especially emphysema, present in 46% of patients (with
alpha-1-antitrypsin deficiency in 13% of COPD patients),
were common causes of severe Kco impairment. In the
National Emphysema Treatment Trial, mean TLco was
28.4  9.7% of predicted values in a series of 609 patients
with severe emphysemamanagedmedically,4 but Kco values
were not reported. A wide range of Kco values may be found
in a population of patients with COPD,28 with severe Kco
reduction, especially in those with prominent emphysema at
imaging. It is noteworthy that all COPD patients with
Table 2 Final diagnosis in 195 patients with severe carbon
monoxide diffusion coefficient impairment.
Diagnosis No. of
patients (%)
Including no.
with pre-
capillary
PH (%)
Chronic obstructive
pulmonary disease
with emphysema
90 (46%) 26 (29%)
Alpha-1-antitrypsin
deficiency
12 (6%) 2 (17%)
Interstitial lung disease 55 (28%) 29 (53%)
Idiopathic pulmonary
fibrosis
10 (5%) 5 (50%)
Other idiopathic
interstitial pneumonia
8 (4%) 7 (87%)
Lymphangioleiomyomatosis 9 (5%) 3 (33%)
Hypersensitivity
pneumonitis
7 (4%) 3 (43%)
Pulmonary Langerhans
cell histiocytosis
6 (3%) 3 (50%)
Associated with connective
tissue diseasea
6 (3%) 4 (67%)
Sarcoidosis 3 (2%) 3 (100%)
Other interstitial
lung diseaseb
6 (3%) 1 (17%)
Combined pulmonary
fibrosis and emphysema
31 (16%) 15 (48%)
Pre-capillary pulmonary
hypertension
15 (8%) 15 (100%)
Pulmonary arterial
hypertensionc
12 (6%) 12 (100%)
Chronic thromboembolic
pulmonary disease
3 (2%) 3 (100%)
Otherd 4 (2%) 1 (25%)
TOTAL 195 86 (44%)
a Systemic sclerosis, 5 patients; systemic lupus eryth-
ematosus, 1 patient.
b Autoimmune alveolar proteinosis, 2 patients; diffuse lung
involvement with Waldenstro¨m disease, 1 patient; gran-
ulomatosis with systemic vasculitis, 1 patient; idiopathic bron-
chiolitis, 1 patient; interstitial lung disease associated with
small vessel vasculitis, 1 patient.
c Idiopathic, 10 patients; associated with systemic sclerosis, 1
patient; associated with congenital heart disease, 1 patient.
d Cystic lung disease of undetermined cause, 1 patient;
tuberculosis sequelae, 1 patient; graft versus host disease, 1
patient; post-capillary pulmonary hypertension, 1 patient.
Table 3 Main characteristics of 31 patients with combined
pulmonary fibrosis and emphysema (CPFE) syndrome and
severe carbon monoxide transfer coefficient impairment.
Variable Result
Sex, males:females 29:2
Mean age  SD
(range), years
69  8 (54e82)
Smokers: current:
ex-:nevere
13:17:1
Mean pack-years  SD
(range)
40  23 (7e120)
NYHA class II:III:IV 7:22:2
FVC, % predicted 85  17 (52e125)
FEV1, % predicted 76  21 (18e113)
FEV1/FVC, % 67  17 (23e86)
TLC, % predicted 77  18 (49e120)
DLco, % predicted 20  10 (3e39)
Kco, % predicted 23  11 (3e39)
PaO2 at rest, kPa 8  2 (4e12)
6-min walk distance, m 296  135 (20e540)
SpO2 following 6-min
walk test, %
81  9 (64e94)
Decrease in SpO2 during
6-min walk test, %
13  7(28e2)
mPAP, mmHga 43  10 (27e60)
PCWP, mmHga 11  3 (7e14)
CI, L min1 m2a 2.1  0.4 (1.6e3.1)
PVR, dyn s cm5a 741  498 (272e2070)
CI, cardiac index; DLco, single-breath diffusing capacity of the
lung for carbon monoxide; FEV1, forced expiratory volume in
1 s; FVC, forced vital capacity; Kco, single-breath transfer
factor of the lungs for carbon monoxide; mPAP, mean pulmo-
nary arterial pressure; NYHA, New York Heart Association; PaO2,
partial pressure of oxygen in arterial blood; PCWP, pulmonary
capillary wedge pressure; PVR, pulmonary vascular resistance;
SpO2, peripheral oxygen saturation; TLC, total lung capacity.
Data are mean  standard deviation (range).
a In the subgroup of 14 patients with pre-capillary pulmonary
hypertension.
Etiologies of very low Kco 1253Kco < 40% of predicted values in our series had features of
emphysema at chest HRCT. In IPF, TLco diminution is asso-
ciated with decreased survival,5 and TLco < 40% of pre-
dicted values has been proposed as a working definition of
advanced disease.29
The most important finding of our study is that severe
Kco reduction was associated to a combination of several
conditions in most cases, with PH as the major constituent.
Indeed, 36% of patients manifested PH with chronic respi-
ratory parenchymal disease, and 16% of patients had bothemphysema and chronic fibrosing idiopathic interstitial
pneumonia e a condition coined CPFE syndrome27 e
including half of them with associated PH. Overall, 44% of
the patient population had a combination of at least 2 of 3
conditions that may be associated to decreased diffusion
capacity (i.e., ILD, emphysema, and/or PH).
CPFE syndrome, recently individualized27,30 among
smoking-related ILD, is characterized by the combination
of distinct elements, including tobacco smoking, severe
dyspnea, unexpected subnormal spirometry, severely
impaired TLco and Kco, hypoxemia at exercise, and typical
imaging features (centrilobular and/or paraseptal emphy-
sema as well as diffuse interstitial opacities suggestive of
pulmonary fibrosis of the lower lobes). Patients with CPFE
have a higher probability of developing severe pre-capillary
PH than those suffering from IPF without emphysema,31
with PH being the main determinant of mortality.19,27
Most patients with CPFE in this series were not included
in previous reports, yet they had strikingly similar func-
tional and hemodynamic characteristics,27,32e34 specifically
1254 L. Kiakouama et al.with mean Kco of 46  19% of predicted values in CPFE,27
and 28  16% of predicted values in CPFE with associated
PH.19 In patients with CPFE, Kco impairment was strikingly
disproportionate to lung volume reduction (mean Kco, 23%
of predicted values, mean FVC, 85% of predicted values,
mean FEV1, 76% of predicted values), in contrast to that
observed in patients with other ILDs (mean Kco, 30% of
predicted values, mean FVC, 25% of predicted values).
Interestingly, a previous retrospective study has reported
that a combination of emphysema and IPF accounted for the
largest percentage of patients with isolated TLco reduction,
e.g. TLco < 70% of predicted values in a context of nor-
mal lung volume and airflow variables,35 with other causes
represented by ILD, emphysema, pulmonary vascular
disease, and other isolated findings. Although they had
different methodologies, both the study by Aduen et al.35
and the present one concur to indicate that these condi-
tions, and especially a combination of disease processes,
should be searched for in any patient with dyspnea on
exertion and either isolated or severe alteration of diffusion
capacity. When interpreted in conjunction with spirometry
and evaluation of gas exchange, exploration of diffusion
capacity contributes to the diagnostic process and may
orientate us toward relevant investigations (e.g. echocar-
diography and chest HRCT). Low Kco or TLco in the setting of
obstruction or restriction suggests a diagnosis of emphysema
or ILD, respectively, while it should raise the possibility of
CPFE and/or PH in the setting of normal or subnormal
spirometry. Similarly, severe Kco reduction in the setting
of IPF should point to possible associated emphysema and/
or PH.
The frequency of patients with PH in our series is note-
worthy.Previous studieshave shown lowKcovalues inpatients
with IPF, or COPD associated with increased pulmonary pres-
sures.36e38We, therefore,advocate thatechocardiographybe
performed inanypatientwith severeKco reduction. Recently,
attention has focused on a subgroup of patients with COPD,
IPF, or CPFE, with severe “disproportionate” pre-capillary PH
despite long-term oxygen therapy,19,39e42 arbitrarily defined
by mPAP > 35e40 mmHg.26,39 The prevalence of dispropor-
tionate PH has been estimated to be between 0.8% and 5% of
patients with COPD,39,43,44 and 2e9% of patients with IPF
evaluated for lung transplantation,41,42 depending on disease
severity and methodology. Patients with disproportionate PH
are prone to right heart failure andmay share similaritieswith
idiopathicpulmonary arterial hypertension.45,46 Interestingly,
63% of patientswith COPD-, ILD-, or CPFE-associated PH in the
present study had mPAP > 35 mmHg, thus indicating that
chronic parenchymal lung disease with disproportionate PH is
frequent in patients with severely-decreased diffusion
capacity.
Our study has limitations, including its observational
design with retrospective collection of data; however, the
analysis was performed on consecutive PFTs over a 6-year
period in a large database, with only 2.9% of patients
excluded due to missing data, and is therefore represen-
tative. Our results are subject to referral bias, which could
have led to overrepresentation of severe diseases referred
for lung transplantation. The clinical utility of Kco versus
TLco has been questioned, primarily because the relation-
ship between TLco and alveolar volume is not linear47;
however, mean TLco values were similar to those of Kco inour series, and it is very unlikely that different etiologies
would have been observed, had the study been based on
severely-decreased TLco instead of Kco.
In conclusion, severe Kco reduction is frequently related
to pulmonary hypertension, especially when associated
with emphysema and/or interstitial lung disease. System-
atic echocardiography is thus warranted in any patient with
severe Kco diminution.
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